South African Food Review on MSN
Cipla and ImmunoACT launch CAR‑T therapy in Africa
Cipla, a global pharmaceutical leader, has partnered with ImmunoACT to introduce talicabtagene autoleucel in Africa. This is ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...
Cipla Limited, through its subsidiary Medpro Pharmaceutica, has entered into an exclusive license and supply agreement with ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Organizers will sell raffle and 50/50 tickets at the game, with proceeds supporting Colton Strong Kids.
Funding will allow Birmingham researchers to develop new drugs to improve outcomes for children with leukaemia.
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
Cipla Limited partners with ImmunoACT to launch talicabtagene autoleucel CAR-T therapy for blood cancers in South Africa, ...
Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...
Drug firm Cipla on Tuesday said it has tied up with Immunoadoptive Cell Therapy to commercialise talicabtagene autoleucel, an indigenously developed CAR-T ...
Cipla partners with ImmunoACT to commercialise CAR-T cell therapy in South Africa, Algeria, and Morocco. Expanding access to innovative cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results